Literature DB >> 3546403

Review of haloperidol blood level and clinical response: looking through the window.

J Volavka, T B Cooper.   

Abstract

The studies of relationship between haloperidol plasma levels and clinical response in schizophrenia have yielded variable results. A therapeutic window for haloperidol may exist, but the evidence for it is inconsistent. Future studies of this problem using larger patient samples would permit the investigation of interactions between the clinical predictors and the haloperidol plasma levels in the determination of clinical outcome. Although the reduced haloperidol in plasma as well as the red blood cell levels of haloperidol and reduced haloperidol or ratios of the metabolite to parent compound may also be related to clinical outcome, the evidence for this relationship is very tentative. More research is needed before routine clinical monitoring of haloperidol blood levels can be recommended.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3546403

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  12 in total

1.  The effects of levodopa and haloperidol on flash and pattern ERGs and VEPs in normal humans.

Authors:  P Bartel; M Blom; E Robinson; C van der Meyden; D K Sommers; P Becker
Journal:  Doc Ophthalmol       Date:  1990-11       Impact factor: 2.379

Review 2.  Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?

Authors:  W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients.

Authors:  Eiji Yukawa; Tsuyoshi Hokazono; Miho Yukawa; Ritsuko Ichimaru; Takako Maki; Kanemitsu Matsunaga; Shigehiro Ohdo; Motoaki Anai; Shun Higuchi; Yoshinobu Goto
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Haloperidol dosing strategies in the treatment of delirium in the critically ill.

Authors:  Erica H Z Wang; Vincent H Mabasa; Gabriel W Loh; Mary H H Ensom
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

5.  Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients.

Authors:  M W Jann; Y W Lam; W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  Differences between antipsychotic drugs in persistence of brain levels and behavioral effects.

Authors:  B M Cohen; T Tsuneizumi; R J Baldessarini; A Campbell; S M Babb
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  4-(4-Chloro-phen-yl)-1-[3-(4-fluoro-benzo-yl)prop-yl]-4-hydroxy-piperidin-1-ium 2,4,6-trinitro-phenolate (haloperidol picrate).

Authors:  Jerry P Jasinski; Ray J Butcher; Q N M Hakim Al-Arique; H S Yathirajan; B Narayana
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-09-09

Review 8.  The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review.

Authors:  C Simhandl; K Meszaros
Journal:  J Psychiatry Neurosci       Date:  1992-03       Impact factor: 6.186

Review 9.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 10.  Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs.

Authors:  G V Milton; M W Jann
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.